<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220868</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-334-1527</org_study_id>
    <nct_id>NCT02220868</nct_id>
  </id_info>
  <brief_title>Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study</brief_title>
  <official_title>Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Michael's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Michael's Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the
      treatment of hepatitis c in patients taking stribild.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety, efficacy and pharmacokinetics of
      sofosbuvir 400mg once daily plus ribavirin 1000-1200 mg daily in HIV-infected patients on
      fixed dose co-formulation emtricitabine/tenofovir/cobicistat/elvitegravir (Stribild).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>â€¢ SVR,12 defined as undetectable HCV RNA levels for 12 weeks after the completion of therapy</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>patients who have achieved non-detectable HCV levels 12 weeks post treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis C Infection</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Sofossbuvir, Riabvirin, Stribild</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir, Ribavirin, and Stribild</intervention_name>
    <arm_group_label>Sofossbuvir, Riabvirin, Stribild</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Chronic HCV genotype 1 infection

          -  Receiving emtricitabine/tenofovir/cobicistat/elvitegravir for at least 8 weeks.

          -  CD4 count &gt;200 cells/mm3 at screening and no CD4 count &lt;200 in previous 12 weeks

          -  HIV RNA PCR &lt;50 copies/ml at screening and no HIV RNA PCR &gt; 200 copies/ml in previous
             12 weeks

        Exclusion Criteria:

          -  History of integrase inhibitor resistance

          -  History of integrase inhibitor failure

          -  Absolute neutrophil counts under 1500/mm3 ( Black/ African Americans &lt;1200/mm3

          -  Patients with cirrhosis

          -  Platelet count under 90,000 per cubic millimeter

          -  Hemoglobin levels &lt;11 gm/dl in women or &lt;12 gm/dl in men

          -  Previous treatment with a DAA

          -  Hepatocellular carcinoma

          -  AFP&gt;100 ng/mL

          -  hepatitis B virus (HBsAg positive)

          -  Evidence of decompensated liver disease including, but not limited to, a history of
             presence of clinical ascites, bleeding varices, or hepatic encephalopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Slim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Michael's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James P Fallon</last_name>
    <phone>9738772663</phone>
    <email>jfallon@smmcnj.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prerak P Shukla</last_name>
    <phone>9738772735</phone>
    <email>pshukla@smmcnj.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prerak P Shukla</last_name>
      <phone>973-877-2735</phone>
      <email>pshukla@smmcnj.org</email>
    </contact>
    <contact_backup>
      <last_name>Herbert Galang</last_name>
      <phone>9738772735</phone>
      <email>hgalang@smmcnj.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jihad Slim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Jerome, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymund Sison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 19, 2014</lastchanged_date>
  <firstreceived_date>August 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Michael's Medical Center</investigator_affiliation>
    <investigator_full_name>Jihad Slim, MD</investigator_full_name>
    <investigator_title>Chief and Prgram Director, Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <keyword>DAA</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
